Certificate of Analysis

Issued to: NextGen Peptides (distributor), Melbourne, Australia
Lab product code TR30 | Reported 11/07/2026

Manufacturer's QC laboratory report | HPLC-UV / LC-MS | Nitrogen quantification

RESEARCH PEPTIDE | LYOPHILISED POWDER

Tirzepatide 20 mg

NextGen batch NGP2035 | Laboratory lot: N/A | Identity: Confirmed

PURITY (HPLC-UV)
99.83%

NET PEPTIDE CONTENT
31.25 mg

APPEARANCE
White Lyophilised Powder

Analytical results

Test	Method	Specification	Result
Purity	HPLC-UV (LC-MS coupled)	Report value	**99.83%**
Net peptide content	Nitrogen quantification (elemental analyser)	Report value	**31.25 mg**
Identity	Sample summary	Confirmed	**Confirmed**
Identity (LC-MS)	LC-MS	-	**N/A - not reported**
Molecular weight	Mass spectrometry	-	**Per MS (see lab report)**
Endotoxin	Endotoxin analysis	-	**N/A - not tested**
Appearance	Visual	-	**White Lyophilised Powder**

Chromatogram

HPLC-UV trace as issued by the testing laboratory



Sign-off

Tested by: Miss. Xie YuJing, QC Date: 12/07/2026

Reviewed by: Miss. Zhang Bo, QC Date: 12/07/2026

This certificate reproduces the results issued by the manufacturer's quality-control laboratory for the batch supplied to NextGen Peptides, re-set for legibility; all values, methods, signatories and dates are as issued. Purity analysis was conducted by HPLC with UV detection coupled with mass spectrometry (LC-MS/MS) under standard laboratory conditions; net peptide content was determined by nitrogen quantification using an elemental analyser. Results are specific to the sample(s) provided and are for informational purposes only; they should be interpreted by qualified professionals within the scope of the intended research. The peptide tested is supplied strictly for laboratory and in-vitro research use - not for human or veterinary use, nor for diagnostic, therapeutic or clinical applications.